Concepedia

Author

Jyothis T. George

Boehringer Ingelheim (Germany)ORCID

Also Known As

A George, George J., J GEORGE, J George, J George3, J T George, J. George, J. T. George, J.T George, J.T. George

241

Publications

10.4K

Citations

50

H-Index

56

Concepts

All Affiliations

Boehringer Ingelheim (Germany)University of TorontoLunenfeld-Tanenbaum Research InstituteMount Sinai HospitalBoehringer Ingelheim (Norway)
JT

About

Jyothis T. George is an author at Boehringer Ingelheim (Germany) specializing in medicine, cardiovascular disease, and diabetes.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

12

704

2

Diabetes

8

8

482

3

Public Health

7

7

576

4

Emergency Medicine

4

4

255

5

Health Sciences

2

2

54

Jyothis T. George

×

79

Publications

8K

Citations

43

H-Index

YearCitations

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk

Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen,

JAMA

2018

1K

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

Silvio E. Inzucchi, Bernard Zinman, David Fitchett,

Diabetes Care

2017

721

Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes

Julio Rosenstock, Steven E. Kahn, Odd Erik Johansen,

JAMA

2019

578

Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease

Christoph Wanner, John M. Lachin, Silvio E. Inzucchi,

Circulation

2017

462

Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial

David Fitchett, Silvio E. Inzucchi, Christopher P. Cannon,

Circulation

2019

342

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials

Julio Rosenstock, Jan Marquard, Lori M. Laffel,

Diabetes Care

2018

339

Evaluation of the Effects of Sodium–Glucose Co-Transporter 2 Inhibition with Empagliflozin on Morbidity and Mortality in Patients with Chronic Heart Failure and a Preserved Ejection Fraction: Rationale for and Design of the EMPEROR-Preserved Trial

Stefan D. Anker, Javed Butler, Gerasimos Filippatos,

European Journal of Heart Failure

2019

248

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

David Fitchett, Javed Butler, Philippe van de Borne,

European Heart Journal

2017

243

Kisspeptin-10 Is a Potent Stimulator of LH and Increases Pulse Frequency in Men

Jyothis T. George, Johannes D. Veldhuis, Antonia K. Roseweir,

The Journal of Clinical Endocrinology & Metabolism

2011

178

Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial

Naveed Sattar, David Fitchett, Stefan Hantel,

Diabetologia

2018

160

Page 1